3SBio, along with its subsidiaries Shenyang Sunshine Pharmaceutical and 3S Guojian Pharmaceutical (Shanghai), will grant Pfizer exclusive global rights to SSGJ-707 outside of China. Pfizer retains ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese ...

Pfizer Inc. PFE announced Monday it has secured exclusive global rights, excluding China, to 3SBio Inc.‘s bispecific antibody SSGJ-707 in a deal potentially worth up to $6 billion. The agreement ...

Pfizer signs licensing deal worth about $6 billion with China's 3SBio for cancer drug U.S. drugmaker Pfizer said on Monday it has signed a licensing agreement worth about $6 billion with Chinese ...

Pfizer's recent acquisition of global biotech company Seagen marked ... We are eager to strengthen our partnership network, leverage cutting-edge technologies, and introduce new products to ...

Pfizer is expanding its collaboration with the start-up PostEra, which applies artificial intelligence to medicinal chemistry. The pharmaceutical giant will pay the smaller firm up to $350 million ...

No patent infringement found in exports of individual conjugate bulk substances and research-use finished products of PCV13 ...

Pfizer will voluntarily pull its sickle cell disease (SCD) drug Oxbryta from all markets worldwide, a major blow to a $5.4 billion acquisition the New York pharma made two years ago. Pfizer will ...

Pharmaceutical and biotechnology company Pfizer marks 70 years of dedication to its mission of advancing patient health in ...